These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37864642)

  • 21. Bleeding diathesis and hemophilias.
    Amin C; Sharathkumar A; Griest A
    Handb Clin Neurol; 2014; 120():1045-59. PubMed ID: 24365370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
    Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
    J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraxial techniques in obstetric and non-obstetric patients with common bleeding diatheses.
    Choi S; Brull R
    Anesth Analg; 2009 Aug; 109(2):648-60. PubMed ID: 19608843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting von Willebrand disease: the current status and future directions of management therapies.
    Franchini M; Focosi D
    Expert Rev Hematol; 2023; 16(11):871-878. PubMed ID: 37800892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemophilic arthropathy in patients with von Willebrand disease.
    van Galen KP; Mauser-Bunschoten EP; Leebeek FW
    Blood Rev; 2012 Nov; 26(6):261-6. PubMed ID: 23010260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term prophylaxis in von Willebrand disease.
    Berntorp E; Petrini P
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S23-6. PubMed ID: 15849523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease.
    Makris M; Federici AB; Mannucci PM; Bolton-Maggs PHB; Yee TT; Abshire T; Berntorp E
    Haemophilia; 2015 May; 21(3):338-342. PubMed ID: 25381842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dermatologic surgery, hemophilia and Von Willebrand disease].
    Say M; Dupin N; Stieltjes N; Avril MF; Aractingi S; Chanal J
    Ann Dermatol Venereol; 2018 Apr; 145(4):233-239. PubMed ID: 29150153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 3 von Willebrand disease: assessment of complications and approaches to treatment -- results of a patient and Hemophilia Treatment Center Survey in the United States.
    Sumner M; Williams J
    Haemophilia; 2004 Jul; 10(4):360-6. PubMed ID: 15230950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
    Seidi Zadeh O; Ahmadinejad M; Amoohossein B; Homayoun S
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.
    Allan JN; Friedman KD; DeSancho MT
    Int J Hematol; 2014 Dec; 100(6):602-6. PubMed ID: 25212677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of von Willebrand disease in The Netherlands.
    de Wee EM; Leebeek FW; Eikenboom JC
    Semin Thromb Hemost; 2011 Jul; 37(5):480-7. PubMed ID: 22102190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal bleeding in von Willebrand patients: special diagnostic and management considerations.
    Ocran E; Chornenki NLJ; Bowman M; Sholzberg M; James P
    Expert Rev Hematol; 2023; 16(8):575-584. PubMed ID: 37278227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do patients with haemophilia and von Willebrand disease with arterial hypertension have bleeding complications: a German single centre cohort.
    Alesci RS; Krekeler S; Seifried E; Miesbach W
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):320-3. PubMed ID: 22473050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posttonsillectomy hemorrhage in children with von Willebrand disease or hemophilia.
    Sun GH; Auger KA; Aliu O; Patrick SW; DeMonner S; Davis MM
    JAMA Otolaryngol Head Neck Surg; 2013 Mar; 139(3):245-9. PubMed ID: 23657425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.
    Rose EH; Aledort LM
    Ann Intern Med; 1991 Apr; 114(7):563-8. PubMed ID: 1900403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease.
    Mannucci PM; Cattaneo M
    Haemostasis; 1992; 22(5):276-80. PubMed ID: 1478539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.